Steven Hall

Royal Society Newton International Fellow

Steve completed his BSc with First Class Honours in 2011 at Mount Allison University, a small school in New Brunswick, Canada. He then moved to Halifax, Nova Scotia, where he obtained his PhD in Pharmacology from Dalhousie University in 2017. He received a Mitacs Elevate Fellowship for his first postdoctoral fellowship (2017-2019), which he completed in collaboration with a local nutraceutics company in Halifax along with Dalhousie's College of Pharmacy. In February of 2020, after receiving a Newton International Fellowship through the Royal Society, he moved across the Atlantic to join the Centre for Snakebite Research and Interventions. 

Research

The discovery and study of small molecule therapeutics as treatments for snakebite-induced local tissue damage, such as necrosis. 

Recent publications: 

    Selected publications

    • Clare, Rachel H.*, Steven R. Hall*, Rohit N. Patel, and Nicholas R. Casewell. Small Molecule Drug Discovery for Neglected Tropical Snakebite. Trends in Pharmacological Sciences. 2021;1-14. doi: 10.1016/j.tips.2021.02.005. *Co-first authorship as these authors contributed equally to this work.

      Hall, Steven R., Anna-Jean Reid, Jasmine Eng, Brendan T. McKeown, Marc St-Onge, and Kerry B. Goralski. A Lipid-Based Oral Supplement Protects Skin Cells in Culture from Ultraviolet Light and Activates Antioxidant and Anti-Inflammatory Mechanisms. Journal of Natural Health Product Research. 2020;2(1):1-14. doi:10.33211/jnhpr.10.

      Hall, Steven R. and Kerry Brennan Goralski. ZATT, TDP2, and SUMO2: Breaking the tie that binds TOP2 to DNA. Translational Cancer Research. 2018;7:S439-S444. doi:10.21037/tcr.2018.02.03.

      Hall, Steven R., Jay Toulany, Leah G. Bennett, Camilo F. Martinez-Farina, Andrew W. Robertson, David L. Jakeman, and Kerry B. Goralski. Jadomycins inhibit type II topoisomerases and promote DNA damage and apoptosis in multidrug-resistant triple-negative breast cancer cells. Journal of Pharmacology and Experimental Therapeutics. 2017;363(2):196-210. doi:10.1124/jpet.117.241125.

      Hall, Steven R., Heather L. Blundon, Matthew A. Ladda, Andrew W. Robertson, Camilo F. Martinez-Farina, David L. Jakeman, and Kerry B. Goralski. Jadomycin breast cancer cytotoxicity is mediated by a copper-dependent, reactive oxygen species-inducing mechanism. Pharmacology Research & Perspectives. 2015;3(2):1-16. doi:10.1002/prp2.110.